1.Organization, W.H., Health topics. Vaccines. 2019.
2.Orenstein, W.A. and R. Ahmed, Simply put: Vaccination saves lives. 2017, National Acad Sciences. p. 4031-4033.
3.Gebre, M.S., et al., Novel approaches for vaccine development. Cell, 2021. 184(6): p. 1589-1603.
4.Pandey, A. and A.P. Galvani, The global burden of HIV and prospects for control. The Lancet HIV, 2019. 6(12): p. e809-e811.
5.Riedel, S. Edward Jenner and the history of smallpox and vaccination. in Baylor University medical center proceedings. 2005. Taylor & Francis.
6.Demento, S.L., et al., Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials, 2012. 33(19): p. 4957-4964.
7.Tsoras, A.N. and J.A. Champion, Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications. Annual Review of Chemical and Biomolecular Engineering, 2019. 10: p. 337-359.
8.Black, M., et al., Self‐assembled peptide amphiphile micelles containing a cytotoxic T‐cell epitope promote a protective immune response in vivo. Advanced Materials, 2012. 28(24): p. 3845-3849.
9.Vajdy, M., Immunomodulatory properties of vitamins, flavonoids and plant oils and their potential as vaccine adjuvants and delivery systems. Expert opinion on biological therapy, 2011. 11(11): p. 1501-1513.
10.Yang, L., et al., Design of nanomaterial based systems for novel vaccine development. Biomaterials science, 2016. 4(5): p. 785-802.
11.Irvine, D.J., M.A. Swartz, and G.L. Szeto, Engineering synthetic vaccines using cues from natural immunity. Nature materials, 2013. 12(11): p. 978-990.
12.Welch, R.P., et al., Protein–polymer delivery: Chemistry from the cold chain to the clinic. Bioconjugate Chemistry, 2018. 29(9): p. 2867-2883.
13.Bartok, E. and G. Hartmann, Immune sensing mechanisms that discriminate self from altered self and foreign nucleic acids. Immunity, 2020. 53(1): p. 54-77.
14.Stewart, J. and D. Weir, Innate and acquired immunity. Medical Microbiology, edited by Greenwood D. New York: Churchill Livingstone, 2012: p. 109-135.
15.Barouch, D.H. and L.J. Picker, Novel vaccine vectors for HIV-1. Nature Reviews Microbiology, 2014. 12(11): p. 765-771.
16.Champion, C.R., Heplisav-B: a hepatitis B vaccine with a novel adjuvant. Annals of Pharmacotherapy, 2021. 55(6): p. 783-791.
17.Vartak, A. and S.J. Sucheck, Recent advances in subunit vaccine carriers. Vaccines, 2016. 4(2): p. 12.
18.Kheirvari, M., H. Liu, and E. Tumban, Virus-like particle vaccines and platforms for vaccine development. Viruses, 2023. 15(5): p. 1109.
19.Bachmann, M.F. and G.T. Jennings, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Reviews Immunology, 2010. 10(11): p. 787-796.
20.Chackerian, B., M.R. Durfee, and J.T. Schiller, Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. The Journal of Immunology, 2008. 180(9): p. 5816-5825.
21.Yuseff, M.-I., et al., How B cells capture, process and present antigens: a crucial role for cell polarity. Nature Reviews Immunology, 2013. 13(7): p. 475-486.
22.Zabel, F., T.M. Kündig, and M.F. Bachmann, Virus-induced humoral immunity: on how B cell responses are initiated. Current opinion in virology, 2013. 3(3): p. 357-362.
23.Pardi, N., M.J. Hogan, and D. Weissman, Recent advances in mRNA vaccine technology. Current opinion in immunology, 2020. 65: p. 14-20.
24.Schlake, T., et al., Developing mRNA-vaccine technologies. RNA biology, 2012. 9(11): p. 1319-1330.
25.Suschak, J.J., J.A. Williams, and C.S. Schmaljohn, Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human vaccines & immunotherapeutics, 2017. 13(12): p. 2837-2848.
26.Pardi, N., et al., In vitro transcription of long RNA containing modified nucleosides. Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and Protocols, 2013: p. 29-42.
27.Weissman, D., et al., HPLC purification of in vitro transcribed long RNA. Synthetic messenger RNA and cell metabolism modulation: Methods and protocols, 2013: p. 43-54.
28.Karikó, K., et al., Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic acids research, 2011. 39(21): p. e142-e142.
29.Thess, A., et al., Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Molecular Therapy, 2015. 23(9): p. 1456-1464.
30.Sahin, U., K. Karikó, and Ö. Türeci, mRNA-based therapeutics—developing a new class of drugs. Nature reviews Drug discovery, 2014. 13(10): p. 759-780.
31.Pardi, N., et al., mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 2018. 17(4): p. 261-279.
32.Kowalski, P.S., et al., Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Molecular Therapy, 2019. 27(4): p. 710-728.
33.Verbeke, R., et al., The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 2021. 333: p. 511-520.
34.John, S., et al., Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine, 2018. 36(12): p. 1689-1699.
35.Espeseth, A.S., et al., Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. npj Vaccines, 2020. 5(1): p. 16.
36.Lemarchand, P., et al., Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proceedings of the National Academy of Sciences, 1992. 89(14): p. 6482-6486.
37.Sakurai, F., M. Tachibana, and H. Mizuguchi, Adenovirus vector-based vaccine for infectious diseases. Drug Metabolism and Pharmacokinetics, 2022. 42: p. 100432.
38.Hage, E., et al., Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient. Journal of General Virology, 2015. 96(9): p. 2734-2742.
39.Usman, N. and M. Suarez, Adenoviruses. 2020.
40.    Luzuriaga, M.A., et al., Biomaterials and nanomaterials for sustained release vaccine delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021. 13(6): p. e1735.
41.Shen, Y., et al., Applications and perspectives of nanomaterials in novel vaccine development. MedChemComm, 2018. 9(2): p. 226-238.
42.Uppu, D.S., et al., Temporal release of a three-component protein subunit vaccine from polymer multilayers. Journal of controlled release, 2020. 317: p. 130-141.
43.Elmowafy, E.M., M. Tiboni, and M.E. Soliman, Biocompatibility, biodegradation and biomedical applications of poly (lactic acid)/poly (lactic-co-glycolic acid) micro and nanoparticles. Journal of Pharmaceutical Investigation, 2019. 49: p. 347-380.
44.Sahdev, P., L.J. Ochyl, and J.J. Moon, Biomaterials for nanoparticle vaccine delivery systems. Pharmaceutical research, 2014. 31: p. 2563-2582.
45.Bachelder, E.M., et al., Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. Journal of the American Chemical Society, 2008. 130(32): p. 10494-10495.
46.Huang, C.-H., et al., Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy. Scientific Reports, 2016. 6(1): p. 36732.
47.Lou, P.J., et al., PMMA particle‐mediated DNA vaccine for cervical cancer. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, 2009. 88(4): p. 849-857.
48.Men, Y., et al., Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine, 1997. 15(12-13): p. 1405-1412.
49.Lü, J.-M., et al., Current advances in research and clinical applications of PLGA-based nanotechnology. Expert review of molecular diagnostics, 2009. 9(4): p. 325-341.
50.Silva, A., et al., PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Human vaccines & immunotherapeutics, 2016. 12(4): p. 1056-1069.
51.Nagpal, P.S., et al., Aerosol immunization by alginate coated mycobacterium (BCG/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M. tb. H37Rv infection in mice. BMC Infectious Diseases, 2019. 19: p. 1-14.
52.Sarei, F., et al., Alginate nanoparticles as a promising adjuvant and vaccine delivery system. Indian Journal of Pharmaceutical Sciences, 2013. 75(4): p. 442.
53.Wang, H. and M. Roman, Cellulose-based oral vaccine formulation for influenza virus. Nanomedicine: Nanotechnology, Biology and Medicine, 2016. 2(12): p. 489.
54.Harde, H., A.K. Agrawal, and S. Jain, Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine, 2014. 9(16): p. 2511-2529.
55.Bussio, J.I., C. Molina-Perea, and J.V. González-Aramundiz, Hyaluronic acid nanocapsules as a platform for needle-free vaccination. Pharmaceutics, 2019. 11(5): p. 246.
56.Rydell, N., L. Stertman, and I. Sjöholm, Starch microparticles as vaccine adjuvant. Expert Opinion on Drug Delivery, 2005. 2(5): p. 807-828.
57.Chung, Y.H., et al., COVID-19 vaccine frontrunners and their nanotechnology design. ACS nano, 2020. 14(10): p. 12522-12537.
58.Fries, C.N., et al., Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nature Nanotechnology, 2021. 16(4): p. 1-14.
59.McCann N, O’Connor D, Lambe T, Pollard AJ. Viral vector vaccines. Current Opinion in Immunology. 2022 Aug 1;77:102210.
60.Gharaghie TP, Beiranvand S, Abbas Doosti AH, Ghadiri SH. A review of the epidemiology and clinical signs of SARS-COV-2. NCMB J. 2020;11(41):103-20.
61.Ghourchian H, Pecho RD, Karimi-Dehkordi M, Mazandarani A, Ghajari G, Piri-Gharaghie T. Novel niosome-encapsulated 2, 5-Diketopiperazine (BHPPD): synthesis, formulation, and anti-breast cancer activity. Applied Biochemistry and Biotechnology. 2024 Jun;196(6):3126-47.
62.Piri Gharaghie T, Beiranvand S, Ghadiri A, Hajimohammadi S. A Review of Bioinformatics Studies on the Function of Structural and Nonstructural Proteins and the Level of Glycoprotein Inhibiting Heme Metabolism by SARS-CoV-2 Virus. Jundishapur Scientific 63Medical Journal. 2022 May 22;21(2):176-93.
63.Ghajari G, Moosavi R. Evaluation of the effects of diazinon toxin on some reproductive parameters in male rats. Personalized Medicine Journal. 2022 Jun 20;7(25):30-5.